Abstract

A 5-year-old, Terrier breed dog having the complaints of anestrus, polyuria, polydipsia and alopecia referred to Small Animal Veterinary Teaching Hospital. Paraclinical and clinical assessments confirmed the diagnosis of pituitary-dependent hyperadrenocorticism and Mitotane (25 mg/kg BID 5 days) prescribed. The dog was presented to clinic with the signs of vomiting, ataxia and weakness after two weeks. The owner reported that Mitotane therapy continued for 14 days without decreasing the dosage contrary to what is describe. Routin blood work and basal cortisol concentration revealed severe hypoglycemia and hypocortisolemia. Methylprednisolone acetate and supportive therapy were initiated. The dog died after three weeks according to owner’s information. This case report emphasized that one of the possible complication of Mitotane therapy is hypoadrenocorticism.

Keywords: Mitotane, Hypoadrenocorticism, Dog, Hyperadrenocorticism

INTRODUCTION

Cushing’s disease is a common endocrinological disorder of middle to old age dogs. A breed predisposition has been particularly noted in the Miniature Poodles, German Shepherds, Dachshunds, Boxers, Terriers and Beagles [1]. Cushing’s Syndrome is characterised by the symptoms of polyuria, polydipsia, polyphagy, alopecia, pendulous abdomen, lethargy, recurrent urinary tract disease, hypotrichosis, hyperpigmentation, comedones and calcinosis cutis. Less common symptoms include hypertension, pulmonary thromboembolism, testicular atrophy, clitoral hypertrophy, anestrus, facial paralysis and corneal ulceration [2]. Pituitary-dependent hyperadrenocorticism (PDH) is responsible for 80% of all naturally occurred cases and more than 90% of dogs with PDH have a pituitary tumor. The pituitary tumors secreting excessive amounts of cortisol could be tiny (microadenoma) not easily identified by magnetic resonance imaging (MRI) [3].

Dogs with Cushing’s disease have the stress leukogram,
thrombocytosis (403,000-1,140,000 platelet/µl) and remarkable elevation of serum alkaline phosphatase level [4]. Hypercortisolemia is the most prominent sign for the Cushing’s disease [5]. Thyroid hormone levels may be slightly low because of the suppression of glucocorticoids on TSH in dogs with Cushing’s disease [3]. Adrenocorticotropic hormone stimulation and low-high dose dexamethasone suppression tests may be required for a definite diagnosis. Useful diagnostic tools to identify etiopathologic changes in Cushing’s disease include abdominal radiography, ultrasonography and MRI. Options of surgery, radiation, adrenalectomy, hypophysectomy or medical therapy (Mitotane, Trilostane etc.) have been reported for treating hyperadrenocorticism in dogs [5].

Hypoadrenocorticism as an overlooked condition results from primary or secondary etiological reasons. Mitotane used for the control of PDH causes selective and progressive necrosis, cytotoxic effects on adrenal cortex and iatrogenic hypoadrenocorticism even when carefully procedure of dosing [6,7].

The purpose of this case report is to focus on the monitoring of Mitotane therapy in a dog with hyperadrenocorticism.

**CASE HISTORY**

A 5-year-old, 12 kg female, Terrier breed dog having the complaints of anestrus, polyuria, polydipsia and alopecia referred to Small Animal Veterinary Teaching Hospital. Alopecia, thin skin with hyperpigmentation, calcinosis cutis and vascularization and, pendulous abdomen were remarkable in physical examination (Fig. 1-2). Initial diagnostic tests included complete blood count (CBC), liver function (Alkaline phosphatase, Alanin aminotranspherase, Aspartate aminotransferase, Gamma-glutamyl transferase), some electrolyte analysis (Sodium, Potassium, Chloride) and high dose dexamethasone suppression test. CBC revealed no abnormalities. High alkaline phosphatase (1301 IU/L; reference range [8], 20-156 IU/L), alanine aminotransferase (309 IU/L; reference range [8], 21-102 IU/L), glutamyl transferase (353 IU/L; reference range [8], 1.2-6.4 IU/L) and slightly elevated aspartate aminotransferase (93 IU/L; reference range [8], 23-66 IU/L) were noted. Serum sodium (149 mmol/l), potassium (3.9 mmol/l) and chloride (111 mmol/l) concentrations were obtained. The sodium:potassium (Na:K) ratio was 38 (reference range, 27-40 [8]). The analysis revealed total thyroxine (tT₄) and free thyroxine (fT₄) concentrations as 1.30 µg/dl and 7.00 pmol/L respectively (tT₄, reference range, 1.20-3.00 µg/dl; fT₄, reference range, 9.00-42.50 pmol/L). An increase in basal cortisol levels (28.50 µg/dl; reference range [8], 0.96-6.81 µg/dl) was also determined. The presence of hepatomegaly was
detected by abdominal ultrasonography. Any adrenal or pituitary masses and contour deformities were defined by ultrasonography and MRI (Fig. 3). High dose Dexamethasone suppression test (0.1 mg/kg dexamethasone IV) was performed for the suspicion of hyperadrenocorticism. Post-dexamethasone cortisol concentrations were 6.1 µg/dl and 0.3 µg/dl at 4 and 6 h respectively. Paraclinical and clinical assessments confirmed the diagnosis of PDH. Mitotane (Lysodren®; 25 mg/kg BID 5 days) was prescribed for the dog. Fourteen days later the dog was presented to clinic with the signs of vomiting, ataxia and weakness. The owner reported that Mitotane therapy continued for 14 consecutive days in the same dose. Routin blood work and basal cortisol concentration revealed severe hypoglycemia (44 mg/dl; reference range [8], 70-120 mg/dl) and hypocortisolemia (<0.1 ng/dl; reference range [8], 1-6 µg/dl). In spite of optimal medical therapy with Methylprednisolone acetate (Prednol tablet®; 1 mg/kg) and supportive therapy, the dog died three weeks later.

**DISCUSSION**

Although new therapeutic options have been introduced, Mitotane is still the most common medical therapy for hyperadrenocorticism in dogs [9]. The therapeutic goal of the Mitotane as an adrenocorticolytic agent for dogs with PDH should be to provide the relatively hypoadrenal state without causing excessive Adrenocorticotropic hormone stimulation. For decreasing serum cortisol concentration, induction therapy with Mitotane is initiated at a dose of 25 mg/kg BID for 5 following days. Cortisol concentration falls in reference range during the induction phase. After induction therapy, Mitotane is administered for two times in a week with decreasing the dosage [10]. The adverse effects of Mitotane therapy associated with the gastrointestinal and neurologic signs can develop during the induction phase. The adverse effects include anorexia, episodes of vomiting, diarrhea, ataxy and weakness and decreases in water consumption. Long term Mitotane administration in induction phase may cause addisonian crisis [10]. In a study of 200 dogs treated with induction doses of Mitotane, adverse effects developed in 50 dogs [10]. In this case report, using Mitotane for 14 days by the owner instead of 5 days caused adverse effects and death in a dog with hyperadrenocorticism.

Veterinarians should be careful during the therapy period while using Mitotane in dogs. It is a necessity to follow the adverse clinical signs by the owners. In the third day of the induction phase (25 mg/kg BID), identifying the basal cortisol levels to prevent addisonian crisis may be lifesaving.

**REFERENCES**